Dr. Jack West reviews evidence that a subset of patients with advanced NSCLC demonstrate “hyper-progressing disease” (HPD), worsening cancer at a faster rate, on immune checkpoint inhibitor therapy, more commonly than seen in patients on chemotherapy.
Hyper-Progressive Disease on Immunotherapy in Advanced NSCLC (BMIC-012)
